Agendia to Present New Data at SABCS 2019 Demonstrating How Comprehensive Genomic Profiling Benefits Early-Stage Breast Cancer Patients
PRESS RELEASE Data evaluating MammaPrint® and BluePrint® includes new risk Read More
Agendia Presents New Data on the Biological Characteristics of Patients within Extreme Low Risk and High Risk MammaPrint Subgroups at the European Society for Medical Oncology (ESMO)
PRESS RELEASE IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – Read More
Agendia Announces Publication of Study Validating Use of MammaPrint and BluePrint Molecular Diagnostics using Targeted RNA Next-Generation Sequencing Technology
PRESS RELEASE IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – Read More
BluePrint® Identifies Genomic Subtypes for African-American Breast Cancer Patients with Low Risk Outcomes
PRESS RELEASE New data presented at ASCO underscores importance of Read More
Agendia Appoints Two Industry Veterans to Board of Directors
PRESS RELEASE IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – 31 Read More
Agendia and Imegen Announce an Exclusive Distribution Agreement for MammaPrint® and BluePrint® in Spain and Portugal
PRESS RELEASE IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – 21 Read More
New Data Show BluePrint® Identifies Estrogen Receptor Positive Breast Cancer Patients With Poor Response To Anti-Estrogen Therapy Who May Benefit From Neoadjuvant Chemotherapy
PRESS RELEASE ER+ breast cancer patients reclassified as ER+ basal-type Read More
Agendia Announces Creation of New Center of Innovation and R&D Excellence
PRESS RELEASE Simultaneous creation of Global Lab Center of Excellence Read More
Positive Assessment Issued for Agendia’s MammaPrint®
PRESS RELEASE Determination finds that Agendia’s MammaPrint® Breast Cancer Risk Read More
New Studies Show MammaPrint® and BluePrint® Tests Provide Greater Clarity Regarding Risk of Breast Cancer Recurrence and Classifications for Treatment
PRESS RELEASE New Studies Show MammaPrint® and BluePrint® Tests Provide Read More
